Methysergide indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Methysergide}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS P..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Indications== | ||
For the prevention or reduction of intensity and frequency of vascular headaches in the following kinds of patients: | |||
* Patients suffering from one or more severe vascular headaches per week. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher = | date = | accessdate = }}</ref> | * Patients suffering from vascular headaches that are uncontrollable or so severe that preventive therapy is indicated regardless of the frequency of the attack.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 19:18, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications
For the prevention or reduction of intensity and frequency of vascular headaches in the following kinds of patients:
- Patients suffering from one or more severe vascular headaches per week.
- Patients suffering from vascular headaches that are uncontrollable or so severe that preventive therapy is indicated regardless of the frequency of the attack.[1]
References
Adapted from the FDA Package Insert.